Metoject® PEN

Metoject® PEN Administration Guide

Metoject® PEN administration guidelines

About Metoject® PEN

Metoject® PEN is a licensed, single use, 50mg/ml pre-filled single use device for subcutaneous methotrexate injection.

Therapeutic Indications1

Metoject® PEN is indicated for the treatment of:

  • Active rheumatoid arthritis in adult patients
  • Polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate
  • Moderate to severe psoriasis in adult patients who are candidates for systemic therapy, and severe psoriatic arthritis in adults
  • Mild to moderate Crohn’s disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines

Reference
1. Metoject® Summary of Product Characteristics (SmPC)

Metoject® PEN SPC

Metoject® PEN SPC

Metoject® PEN Prescribing Information

Metoject® PEN abbreviated prescribing information

Adverse Events

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to medac drug safety at: drugsafety@medac.de

Contact us

For further information on Metoject® PEN, please contact:

medac Pharma
T: 01786 458086
E: info@medacpharma.co.uk
W: medacpharma.co.uk